» Articles » PMID: 35984590

Cannabinoid Type 1 Receptors in the Basolateral Amygdala Regulate ACPA-Induced Place Preference and Anxiolytic-Like Behaviors

Overview
Journal Neurochem Res
Specialties Chemistry
Neurology
Date 2022 Aug 19
PMID 35984590
Authors
Affiliations
Soon will be listed here.
Abstract

The number of cannabis users is increasing in the world. However, the mechanisms involved in the psychiatric effects and addiction formation remain unclear. Medical treatments against cannabis addiction have not yet been established. Δ9-Tetrahydrocannabinol (THC), the main active substance in cannabis, binds and affects cannabinoid type 1 receptors (CB1R) in the brain. The mice were intraperitoneally (i.p.) administered arachidonylcyclopropylamide (ACPA), a CB1R-selective agonist, and then two behavioral experiments on anxiety and addiction were performed. Administration of ACPA caused anxiolytic-like behavior in the elevated plus maze test. In addition, ACPA increased place preference in a conditioned place preference (CPP) test. The basolateral amygdala (BLA), which is the focus of this study, is involved in anxiety-like behavior and reward and is reported to express high levels of CB1R. We aimed to reveal the role of CB1R in BLA for ACPA-induced behavior. AM251, a CB1R selective antagonist, was administered intra-BLA before i.p. administration of ACPA. Intra-BLA administration of AM251 inhibited ACPA-induced anxiolytic-like behavior and place preference. These results suggest that CB1R in the BLA contributes to behavior disorders caused by the acute or chronic use of cannabis.

Citing Articles

Cholecystokinin-expressing interneurons mediated inhibitory transmission and plasticity in basolateral amygdala modulate stress-induced anxiety-like behaviors in mice.

Fang W, Chen X, He J Neurobiol Stress. 2024; 33:100680.

PMID: 39502835 PMC: 11536064. DOI: 10.1016/j.ynstr.2024.100680.


Endogenous Regulator of G protein Signaling 14 (RGS14) suppresses cocaine-induced emotionally motivated behaviors in female mice.

Bramlett S, Foster S, Weinshenker D, Hepler J bioRxiv. 2024; .

PMID: 39314405 PMC: 11419016. DOI: 10.1101/2024.09.12.612719.


Neuroprotection and Beyond: The Central Role of CB1 and CB2 Receptors in Stroke Recovery.

Bietar B, Tanner S, Lehmann C Int J Mol Sci. 2023; 24(23).

PMID: 38069049 PMC: 10705908. DOI: 10.3390/ijms242316728.


Sleep disturbance after cessation of cannabis administration in mice.

Asano T, Takemoto H, Horita T, Tokutake T, Izuo N, Mochizuki T Neuropsychopharmacol Rep. 2023; 43(4):505-512.

PMID: 36905178 PMC: 10739061. DOI: 10.1002/npr2.12329.


Shati/Nat8l Overexpression Improves Cognitive Decline by Upregulating Neuronal Trophic Factor in Alzheimer's Disease Model Mice.

Chino K, Izuo N, Noike H, Uno K, Kuboyama T, Tohda C Neurochem Res. 2022; 47(9):2805-2814.

PMID: 35759136 DOI: 10.1007/s11064-022-03649-2.

References
1.
Cohen K, Weizman A, Weinstein A . Positive and Negative Effects of Cannabis and Cannabinoids on Health. Clin Pharmacol Ther. 2019; 105(5):1139-1147. DOI: 10.1002/cpt.1381. View

2.
Whiting P, Wolff R, Deshpande S, Di Nisio M, Duffy S, Hernandez A . Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015; 313(24):2456-73. DOI: 10.1001/jama.2015.6358. View

3.
Koppel B, Brust J, Fife T, Bronstein J, Youssof S, Gronseth G . Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014; 82(17):1556-63. PMC: 4011465. DOI: 10.1212/WNL.0000000000000363. View

4.
Sachs J, McGlade E, Yurgelun-Todd D . Safety and Toxicology of Cannabinoids. Neurotherapeutics. 2015; 12(4):735-46. PMC: 4604177. DOI: 10.1007/s13311-015-0380-8. View

5.
Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G . Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ. 2002; 325(7374):1199. PMC: 135490. DOI: 10.1136/bmj.325.7374.1199. View